---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-032672"
form_type: "8-K"
ticker: "TVGN"
cik: "0001860871"
company_name: "Tevogen Bio Holdings Inc."
filed_at: "2023-09-14T23:59:59+00:00"
generated_at: "2026-06-10T17:55:36.095328+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Semper Paratus files S-4 for merger with Tevogen Bio; expects close near end of 2023

## Summary
- Filed Registration Statement on Form S-4 with SEC for proposed business combination with Tevogen Bio.
- Combined company to be named Tevogen Bio Holdings Inc., expected to trade on NYSE American as TVGN/TVGNW.
- Transaction approved by both boards; closing subject to SEC review, shareholder approval, and other conditions.
- Tevogen Bio is a clinical-stage immunotherapy company developing off-the-shelf T cell therapies in virology, oncology, neurology.

## SEC filing metadata
- accession: 0001493152-23-032672
- form_type: 8-K
- ticker: TVGN
- cik: 0001860871
- company_name: Tevogen Bio Holdings Inc.
- filed_at: 2023-09-14T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860871/000149315223032672/0001493152-23-032672-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860871/000149315223032672/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-032672
- JSON: https://secwatch.observer/filing/0001493152-23-032672.json
- Plain text: https://secwatch.observer/filing/0001493152-23-032672.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.